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ute to the optimization of its dosing. The aim of this study was to 
evaluate the influence of genetic and clinical factors on TAC phar-
macokinetic variability in stable pediatric renal transplant patients.
Patients (or Materials) and Methods: This study was nested in a 
previous Prograf® to Advagraf® conversion clinical trial in pediat-
ric patients (Eudra CT: 2009-017600-89). Tacrolimus pharmacoki-
netic analysis was performed using a noncompartmental analysis. 
CYP3A5 (*3 rs776746 C> G), ABCB1 (rs1045642 C> T), POR (*28 
rs1057868 C> T and rs2868177 A> G) genotypes were determinate 
by RT-PCR using commercial Taqman® assays. The impact of indi-
vidual genetic variants on TAC AUC0–24 (adjusted by administered 
dose/kg) was evaluated and an additive unweighted genetic score was 
build. Multivariate linear regression was performed including genetic 
(genetic score), demographic, and clinical information as independ-
ent variables and TAC weight-adjusted apparent oral clearance as 
dependent variable.
Results: Twenty-one kidney transplant pediatric patients (aged 
between 4 and 17 years) on stable TAC dose were included (12 
males and 9 females). Mean (SD) body weight was 42.85 (15.42) kg. 
Subjects homozygote for CYP3A5*3 and the carriers of rs1045642, 
rs1057868, or rs2868177 have higher exposure to TAC than noncar-
riers (P < 0.05). Genetic score groups was as follows: 0 (Group 1), 1 
(Group 2), 2 (Group 3), 3 (Group 4), and 4 (Group 5) genetic variants 
in CYP3A5, ABCB1, and POR genes. There was an increase in TAC 
dose/kg adjusted AUC as the number of variants in genetic score 
increase (tendency P = 0.023) and its value is 288% higher in group 
5 compared with group 1. Genetic score, BMI, and concomitant 
deflazacort use were the only covariates retained in the multivariate 
regression model that explained 64.4% of weight-adjusted apparent 
oral clearance total variability. Genetic score, the concomitant def-
lazacort use and BMI explained 33%, 18%, and 15.4% of the total 
variability, respectively. Mean absolute error (SD) of the predicted 
weight-adjusted apparent oral clearance was of 32.82% (23.36%).
Conclusion: Genetic score composed by variants in CYP3A5, 
ABCB1, and POR genes, along BMI and concomitant deflazacort 
use, explain a clinically significant amount of the variability in oral 
clearance of tacrolimus. Larger studies are needed to evaluate the 
potential utility of these variables in predictive TAC dosing algo-
rithms.
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Introduction: The neurotransmitter serotonin (5-hydroxytryptamine; 
5-HT) 5-HT is actively cleared from synaptic spaces by SLC6A4, a 
high-affinity, Na+-, and Cl--dependent transporter localized in pre-
synaptic neuronal membranes. This brain 5-HT transporter appears 
to be a principal site of action of many antidepressant drugs including 
those of the tricyclic, SSRIs, and SSNRIs class. Many patients with 
depression are drug resistant. We hypothesized that changes in the 
transporter protein due to coding single nucleotide polymorphisms 
(SNPs) in SLC6A4 may affect transporter–drug interactions and thus 
may contribute to the resistance to antidepressant drug treatment.
Patients (or Materials) and Methods: We screened SNP databases 
(dbSNP, 1000 Genomes, ESP) for natural variants in the human 
SLC6A4 gene. We specifically focused on nonsynonymous SNPs (nsS-
NPs); that is, SNPs located in coding regions and resulting in amino 
acid variation in protein products of genes. The impact of amino acid 
substitutions caused by nsSNPs in SLC6A4 on the structure and func-
tion of SERT was investigated by using 6 different in silico prediction 
tools. Based on the crystal structure of the bacterial homologue LeuT, 
a homology model of SERT was performed, and the positions of the 
amino acid substitutions relative to the proposed substrate binding 
pocket were identified. A rating scale integrating results from in silico 
predictions and 3D modeling was applied to extract those nsSNPs 
with a potentially high impact on the structure and function of SERT. 
For future in vitro testing in transfected cells, these mutations were 
inserted in an expression vector by site-directed mutagenesis.
Results: We identified 6 nsSNPs within the SLC6A4 gene with poten-
tial effects on protein function. Two of them (H143Y and R144Q) 
reside nearby the cytoplasmatic pore between helix 2 (H2) and H3, 
which is involved in substrate binding. In both cases, the mutation 
results in a charge change and most likely in an altered pore opening 
of SERT. The third SNP (isoleucine 179 to valine) protrudes into the 
predicted binding cavity of inhibitor and substrate and therefore may 
influence substrate–transporter interaction. Another SNP causes the 
expression of a polar threonine 270 instead of a hydrophobic iso-
leucine also projecting into the cytoplasmic pore region. The P339L 
SNP is expected to destabilize H6, which is involved in substrate and 
inhibitor binding. The V488M SNP in H10 is close to the extracel-
lular pore and may affect antidepressant binding.
Conclusion: By applying a comprehensive screening approach, we 
identified 6 naturally occurring nsSNPs that are expected to affect 
substrate (5-HT) and inhibitor (antidepressant drug) binding to 
SERT. We generated transiently transfected cell lines expressing the 
6 variants. Future experiments will have to demonstrate the effects of 
these SNPs on SERT expression and transport function. Of particular 
interest is the impact of the variants on the inhibition of SERT by 
antidepressant drugs.
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Introduction: Voriconazole, an antifungal agent, is metabolized by 
CYP450 2C19 (CYP2C19). CYP2C19 activity is modulated by drug–
drug interactions (DDI) and genetic polymorphisms. We report a 
case of therapeutic use of esomeprazole that “boosted” voriconazole 
plasma concentrations in a CYP2C19 ultrarapid metabolizer HIV 
patient treated with a CYP2C19 inducer among her antiretroviral 
treatment (HAART).
Patients (or Materials) and Methods: A 35-year-old African female 
was diagnosed with AIDS in May 2012. A duodenal histoplasmosis 
and cryptococcosis infections were treated from June 2012 with a 
3-week regimen of amphotericin B–flucytosine then oral voricona-
zole 100 mg BID. HAART was initiated (emtricitabine, tenofovir, 
and raltegravir). Voriconazole doses were increased and given intra-
venously (4 mg/kg/12 h IV) as she developed a single large intrac-
ranial mass. Several voriconazole trough concentrations (C0) were 
measured below the therapeutic range (1.0–4.0 µg/mL). CYP2C19 
genotype was tested and came heterozygous for the variant allele 
CYP2C19*17, which is associated with an ultrarapid phenotype. 
A treatment with esomeprazole 40 mg BID was started and titrated 
because of severe epigastralgia (histoplasmocytosis). Subsequent 
voriconazole C0 were within the therapeutic range. After the proton 
pump inhibitor was switched to ranitidine, voriconazole C0 were 
again infratherapeutic despite an increase in voriconazole doses. 
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Besides several changes in HAART were needed due to resistance or 
persisting replication. After the last change in HAART (darunavir-
ritonavir),voriconazole C0 decreased to 0.25 mg/L (50% decrease). 
Eventually, ranitidine was replaced by esomeprazole 40 mg IV BID. 
Three days later, voriconazole C0 increased 14-fold and voricona-
zole dose could be reduced by 50% to 100 mg (2.5 mg/kg) BID. 
There were no other medication changes. Subsequent voriconazole 
C0 stayed within the therapeutic range.
Results: Voriconazole systemic exposure depends on various factors 
among which CYP 450 activity influenced by genetic polymorphisms 
and DDI. Our patient was heterozygous for the CYP2C19*17 variant 
allele, which has been associated with lower voriconazole AUC com-
pared with wild-type individuals. However, her phenotype indicated 
a reduced activity of CYP2C19.
The change in voriconazole concentrations cannot be explained 
by a DDI with another drug of the antiretroviral treatment.
Conclusion: We report the case of an HIV patient with disseminated 
fungal disease who achieved targeted voriconazole C0 using esome-
prazole as a “booster” to overcome an ultrarapid CYP2C19*17/*1 
genotype and a treatment by a CYP2C19 inducer such as ritonavir. 
Further evaluation is warranted for this "boosting strategy" to define 
the right booster dose, the relevance of this effect in rapid metaboliz-
ers and eventually transferability in clinical setting.
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Introduction: Acamprosate, a homo-taurine analogue, is approved 
for treatment of alcohol dependence. Meta-analyses favor acampro-
sate for its ability to support abstinence, which is the most stable type 
of remission in alcoholics. Yet, only a limited number of treatment-
seeking alcoholics use acamprosate, most likely because of individual 
differences in response and the lack of response predictors.
Patients (or Materials) and Methods: We used a pharmacometabo-
lomics approach to investigate metabolic response in serum amino acid 
metabolites (including acamprosate) between responders and nonre-
sponders to acamprosate treatment. Serum samples were collected 
before and after 3 months of acamprosate treatment. Efficacy was 
defined by self-reported abstinence during acamprosate treatment and 
average γ -glutamyl transferase (GGT) levels at baseline and 3-month 
follow-up were used to confirm abstinence. Of those, 14 responders and 
18 nonresponders comprised an investigation cohort and an additional 
30 responders and 28 nonresponders comprised a replication sample.
Results: Initial metabolite screening was conducted using 32 alco-
hol-dependent subjects. Glutamate levels were significantly higher at 
baseline in the 14 responders compared with the 18 nonresponders 
[t(30) = 2.7, P < 0.05]. After acamprosate treatment, serum glu-
tamate levels in the responder group significantly decreased com-
pared with baseline [t(26) = 3.3, P < 0.05). Similarly, in a replication 
sample of 58 additional alcohol-dependent subjects, responders had 
significantly higher glutamate levels at baseline compared with the 
nonresponder group [t(88) = 2.8, P < 0.05], which decreased signifi-
cantly after acamprosate treatment [t(86) = 3.6, P < 0.05].
Conclusion: Our findings suggest that high glutamate levels may 
be a biomarker to predict the efficacy of acamprosate treatment in 
alcohol-dependent subjects.
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Introduction: Tolperisone, a centrally acting muscle relaxant, is 
used for relieving spasticity of neurological origin and muscle spasm 
associated with painful locomotor diseases. Tolperisone is mainly 
metaolized by CYP2D6 and CYP2C19, CYP1A2, and CYP2B6 are 
also involved in the metabolism of tolperisone. CY2D6 is responsible 
for variablility of drug response, largely due to genetic polymor-
phism. Therefore, we investigated the effects of CYP2D6 genetic 
polymorphism on the pharmacokinetics of tolperisone.
Patients (or Materials) and Methods: Thirty healthy Korean subjects 
were selected and they were divided into 3 different groups according 
to CYP2D6 genotype, CYP2D6*wt/*wt (*wt= *1 or *2, n = 10), 
CYP2D6*wt/*10 (n = 10) and CYP2D6*10/*10 (n = 10). After 
overnight fasting, each subject received a single 150-mg oral dose of 
tolperisone. Blood samples were collected up to 12 hours after drug 
intake, and plasma concentrations of tolperisone were determined 
by using LC-MS/MS analytical system.
Results: Cmax and AUCinf of tolperisone in CYP2D6*10/*10 geno-
type group was significantly higher than those in CYP2D6*wt/*wt 
group (P = 0.0007 and P = 0.0002, respectively). Apparent oral clear-
ance (CL/F) of tolperisone in CYP2D6*wt/*10 and CYP2D6*10/*10 
group was 64% and 75% lower than that in CYP2D6*wt/*wt group 
(P < 0.001 and P = 0.0001, respectively). Among 3 genotypes, differ-
ences in t1/2 of tolperisone were not statistically significant.
Conclusion: Tolperisone is mainly metabolized by CYP2D6 and 
CYP2D6 genetic polymorphism has a significant impact on the phar-
macokinetics of tolperisone.
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Introduction: Human multidrug and toxin extrusion 1 
(hMATE1/SLC47A1) transporter may be involved in the active 
elimination clearance of many cationic drugs in the kidneys. Scarcity 
of knowledge about endogenous substrates of hMATE1 appears to 
hinder exploration of the roles of genetic polymorphisms on the func-
tional activity of hMATE1.
Patients (or Materials) and Methods: Fifty-four healthy volunteers 
(32 males and 22 females; 23 [2] years) underwent 3-hour timed-
urine collection and blood drawing at the midpoint. Plasma and 
urinary levels of N1-methylnicotinamide (MNA) and creatinine 
were measured with a liquid chromatography-mass spectrometry 
system. Renal tubular secretion clearance of MNA (CLTS,MNA) was 
calculated by subtracting the renal clearance of creatinine (a sub-
stitution of glomerular filtration rate) from that of MNA. Genetic 
variants of hMATE1/SLC47A1 and another renal cation transporter, 
hOCT2/SLC22A2, were genotyped by polymerase chain reaction 
followed by direct sequencing. The protocol of the present study was 
